Pedal Me uses high-tech cargo bikes, trailers and trained riders to provide delivery & taxi services when needed. The company offers a solution that will out-perform motors in car-centric cities as bike-friendly measures like bike lanes are introduced. As of now, the company has 32 bikes and 45 staff in total. It has witnessed a strong MoM growth (19% on avg). The trips provided by Pedal Me has negligible carbon footprint in comparison with vans, taxis or electric vehicles. With the funds, the company will improve the technology, maintain speed with demand, develop the staff and balance the process.
days to go:
Expired
investment:
£421,330
Karshare connects renters with owners, giving those with cars the opportunity to earn extra income while those in need of a car can rent from their local community. The company aims to unlock community car sharing by tapping into the estimated 10 million cars parked at UK airports each year and 38 million vehicles parked on UK streets. Karshare's platform features telematics and keyless technology allowing for cars to be booked instantly and unlocked using facial recognition. Karshare has a TrustScore of 4.9/5 and 852 reviews. It has onboarded partners such as Allianz Insurance, OCTO Telematics, Rentalcars.com, and RAC. Karshare has featured in press publications like The Times, Huff Post, BBC and Evening Standard amongst others. The company will use 25% of the investment for business operations, 45% for growing the business, and 31% for developing User Experience (UX) and functionality.
days to go:
Expired
investment:
£1,444,182
Borrow A Boat is a mobile and web-based marketplace that allows users to book all types of boats online for charter, be it on a short-notice request for the day, a long weekend on board, or a 7-14 day boating trip for your summer holiday. The company is providing a 21st-century solution to the people of Britain and changing how people go boating. Till date they have been backed by VC Edition Capital, following on with £1m lead investment with over 22,000 boats listed in over 65 countries. They have been headlined as the sponsor of the UK's biggest boat show in Southampton in 2019.
days to go:
Expired
investment:
£1,325,390
Try EV is a platform that allows customers to discover, analyze, customize and explore with EVs before making a final buying decision. It encourages “electrify to buy” and intends to change the car purchasing process. The company has also collaborated with big brands such as BMW, Tesla, etc. Try Ev was an Exhibitor at London Motor Show 2019, it was shortlisted for “Greener Greenwich” at Greenwich Business Awards and it was an Elevator Pitch Business Awards finalists at London Motor Show 2018. The funds will be used to balance the growth, to bring key talent, to promote partnerships with major leasing companies and charging networks and to improve marketing and promotion efforts.
days to go:
Expired
investment:
£88,430
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Carverter is a technology platform that enables customers to find and lease a hybrid or Electric Vehicle (EV). The company cites data pointing out the UK government's ban on the sale of petrol and diesel only cars after 2030. It also argues about changing car preferences, with 78% of consumers considering leasing to access an EV. Carverter aims to capture this audience and grow its business. The company uses its algorithm to bring together over 32 million data points across its three tools, namely Carvert, Carwizard, and Browse, to help users find their choice of hybrid/EV. Carverter has partnered with renowned entities like WPP, Arval, Microsoft & ITV to boost its business. It will use 10% of the investment on hiring staff, 20% towards rolling out its services across 22 European countries via Arval, and 70% on an advertising multiplier deal with the UK's largest commercial broadcaster, ITV, and WPP.
days to go:
Expired
investment:
£2,324,693
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
WhyBuy is a rental platform that allows a user to rent out items or entities he/she may want to another person. WhyBuy asserts that consumers want to be able to access items for brief periods, and the company aims to be the go-to provider in this segment. It endeavours to save time, space, money and the environment through its business model that is backed by a 100% electric delivery fleet. The company has tested its supply chain to ensure orders are placed despite COVID-19 restrictions. Its app has seen 8000+ downloads from mid-June to end-July 2020 at just over £3 per acquired download across the App Store and Google Playstore. It will use 75% of the investment for marketing, 5% to expand its electric fleet, and 15% as stock and overhead expenses.
days to go:
Expired
investment:
£309,260
